Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EPS (Weighted Average and Diluted) (2018 - 2026)

Ironwood Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 12 years, with the latest figure at -$0.01 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 200.0% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.13, a 1400.0% increase, with the full-year FY2025 number at $0.15, up 1400.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Ironwood Pharmaceuticals, down from $0.23 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for IRWD hit a ceiling of $2.39 in Q2 2021 and a floor of -$6.84 in Q2 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.11 across 5 years, with a median of $0.18 in 2025.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 3357.14% in 2023 and later soared 1500.0% in 2025.
  • Tracing IRWD's EPS (Weighted Average and Diluted) over 5 years: stood at $0.25 in 2021, then rose by 8.0% to $0.27 in 2022, then plummeted by 103.7% to -$0.01 in 2023, then skyrocketed by 200.0% to $0.01 in 2024, then tumbled by 200.0% to -$0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for IRWD at -$0.01 in Q4 2025, $0.23 in Q3 2025, and $0.14 in Q2 2025.